Lomustine 40 mg is often described as a biological lock-pick because it successfully crosses the blood-brain barrier to treat brain cancer and brain tumors. Unlike many therapies that are blocked by the brain's natural defenses, this medication reaches the central nervous system to disrupt the DNA of malignant cells in lung cancer or Hodgkin’s disease. However, patients and doctors must remain vigilant regarding lomustine side effects. These lomustine side effects are unique because they often hit a "nadir" (their lowest point) several weeks after the dose is taken. Because these delayed lomustine side effects require expert monitoring, oncology centers in the UK prioritize securing a reliable supply of lomustine 40 mg. Safety and Sourcing Healthcare providers should note that this drug is not suitable for individuals with severe kidney dysfunction or existing bone marrow suppression. It can also interact negatively with live vaccines. Reach: Exporting to Brazil, Thailand, and Bolivia.